Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Angion Biomedica logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Angion Biomedica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

ANGN MarketRank™: 

Angion Biomedica scored higher than 14% of companies evaluated by MarketBeat, and ranked 877th out of 912 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Angion Biomedica.

  • Earnings Growth

    Earnings for Angion Biomedica are expected to grow in the coming year, from ($1.51) to ($0.53) per share.

  • Short Interest

    There is no current short interest data available for ANGN.
  • Dividend Yield

    Angion Biomedica does not currently pay a dividend.

  • Dividend Growth

    Angion Biomedica does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ANGN.
  • Search Interest

    1 people have searched for ANGN on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Angion Biomedica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.70% of the stock of Angion Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 17.00% of the stock of Angion Biomedica is held by institutions.

  • Read more about Angion Biomedica's insider trading history.
Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

ANGN Stock News Headlines

Akari Therapeutics PLC ADR
OXBDF Oxford Biomedica plc
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
8-K: Angion Biomedica Corp.
See More Headlines

ANGN Stock Analysis - Frequently Asked Questions

Angion Biomedica Corp. (NASDAQ:ANGN) released its earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $1.08 million.

Shares of Angion Biomedica reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Angion Biomedica (ANGN) raised $75 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

Last Earnings
11/12/2021
Today
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,810,000.00
Pretax Margin
-4,456.97%

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
N/A

Miscellaneous

Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ANGN) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners